Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Summary

This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that does not respond to treatment (refractory) and who have MET gene amplification. Crizotinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow.

Timeline

Start

2016-07-29

Primary completion

2022-11-15

Completion

2026-12-31

Publications

• Results Coleman N, Wei Z, Iafrate AJ, Zwiebel JA, Sharon E, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Takebe N, Williams T, Croley JJ, Onitilo AA, Tricoli JV, Cheng J, Karlovich C, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Hong DS, Chen AP, Flaherty KT. Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2. Clin Cancer Res. 2026 Apr 1;32(7):1224-1233. doi: 10.1158/1078-0432.CCR-25-1247.

Drugs

Indications